Advertisement
Screener

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Increase (Decrease) in Contract with Customer, Liability

2.8 / 5 stars · 68/120 Roast Me

ARROWHEAD PHARMACEUTICALS, INC. Increase (Decrease) in Contract with Customer, Liability

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Increase (Decrease) in Contract with Customer, Liability of $123.94 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-04

  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$30.82M.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$8.60M, a 119.87% decline year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $163.36M.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$20.58M.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $2.40M.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$866.00K.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$129.18M.
  • ARROWHEAD PHARMACEUTICALS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$112.50M, a 150.39% decline from fiscal 2021.
Period endIncrease (Decrease) in Contract with Customer, Liability 3 monthIncrease (Decrease) in Contract with Customer, Liability 3 month as first filedIncrease (Decrease) in Contract with Customer, Liability 6 monthIncrease (Decrease) in Contract with Customer, Liability 6 month as first filedIncrease (Decrease) in Contract with Customer, Liability 9 monthIncrease (Decrease) in Contract with Customer, Liability 9 month as first filedIncrease (Decrease) in Contract with Customer, Liability 12 monthIncrease (Decrease) in Contract with Customer, Liability 12 month as first filed
2026-06-30-$30.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04
-$39.42M
derived: sum of 2 quarters · filed 2026-08-04
$123.94M
10-Q · filed 2026-08-04
$103.36M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31-$8.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07
$154.76M
10-Q · filed 2026-05-07
$134.18M
derived: sum of 3 quarters · filed 2026-05-07
$113.89M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$163.36M
10-Q · filed 2026-02-05
$142.78M
derived: sum of 2 quarters · filed 2026-02-05
$122.49M
derived: sum of 3 quarters · filed 2026-08-04
$165.76M
derived: sum of 4 quarters · filed 2026-08-04
2025-09-30-$20.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
-$40.87M
derived: sum of 2 quarters · filed 2026-08-04
$2.40M
derived: sum of 3 quarters · filed 2026-08-04
$2.40M
10-K · filed 2025-11-25
2025-06-30-$20.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04
$22.98M
derived: sum of 2 quarters · filed 2026-08-04
$22.98M
10-Q · filed 2026-08-04
$22.98M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$43.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07
$43.27M
10-Q · filed 2026-05-07
$43.27M
derived: sum of 3 quarters · filed 2026-05-07
$43.27M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$0.00
10-Q · filed 2026-02-05
$0.00
derived: sum of 2 quarters · filed 2026-02-05
$0.00
derived: sum of 3 quarters · filed 2026-02-05
$0.00
derived: sum of 4 quarters · filed 2026-02-05
2024-09-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
$0.00
derived: sum of 2 quarters · filed 2025-11-25
$0.00
derived: sum of 3 quarters · filed 2025-11-25
-$866.00K
10-K · filed 2025-11-25
2024-06-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07
$0.00
derived: sum of 2 quarters · filed 2025-08-07
-$866.00K
10-Q · filed 2025-08-07
-$16.91M
derived: sum of 4 quarters · filed 2025-11-25
2024-03-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12
-$866.00K
10-Q · filed 2025-05-12
-$16.91M
derived: sum of 3 quarters · filed 2025-11-25
-$30.91M
derived: sum of 4 quarters · filed 2025-11-25
2023-12-31-$866.00K
10-Q · filed 2025-02-10
-$16.91M
derived: sum of 2 quarters · filed 2025-11-25
-$30.91M
derived: sum of 3 quarters · filed 2025-11-25
-$107.07M
derived: sum of 4 quarters · filed 2025-11-25
2023-09-30-$16.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25
-$30.05M
derived: sum of 2 quarters · filed 2025-11-25
-$106.20M
derived: sum of 3 quarters · filed 2025-11-25
-$129.18M
10-K · filed 2025-11-25
2023-06-30-$14.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08
-$90.17M
derived: sum of 2 quarters · filed 2024-08-08
-$113.14M
10-Q · filed 2024-08-08
-$138.54M
derived: sum of 4 quarters · filed 2024-11-26
2023-03-31-$76.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09
-$99.14M
10-Q · filed 2024-05-09
-$124.54M
derived: sum of 3 quarters · filed 2024-11-26
-$156.71M
derived: sum of 4 quarters · filed 2024-11-26
2022-12-31-$22.98M
10-Q · filed 2024-02-06
-$48.38M
derived: sum of 2 quarters · filed 2024-11-26
-$80.55M
derived: sum of 3 quarters · filed 2024-11-26
-$108.04M
derived: sum of 4 quarters · filed 2024-11-26
2022-09-30-$25.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26
-$57.58M
derived: sum of 2 quarters · filed 2024-11-26
-$85.06M
derived: sum of 3 quarters · filed 2024-11-26
-$112.50M
10-K · filed 2024-11-26
2022-06-30-$32.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07
-$59.66M
derived: sum of 2 quarters · filed 2023-08-07
-$87.10M
10-Q · filed 2023-08-07
-$75.23M
derived: sum of 4 quarters · filed 2023-11-29
2022-03-31-$27.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02
-$54.93M
10-Q · filed 2023-05-02
-$43.06M
derived: sum of 3 quarters · filed 2023-11-29
-$78.79M
derived: sum of 4 quarters · filed 2023-11-29
2021-12-31-$27.44M
10-Q · filed 2023-02-06
-$15.57M
derived: sum of 2 quarters · filed 2023-11-29
-$51.30M
derived: sum of 3 quarters · filed 2023-11-29
$208.37M
derived: sum of 4 quarters · filed 2023-11-29
2021-09-30$11.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29
-$23.86M
derived: sum of 2 quarters · filed 2023-11-29
$235.81M
derived: sum of 3 quarters · filed 2023-11-29
$223.26M
10-K · filed 2023-11-29
2021-06-30-$35.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-04
$223.94M
derived: sum of 2 quarters · filed 2022-08-04
$211.39M
10-Q · filed 2022-08-04
$204.41M
derived: sum of 4 quarters · filed 2022-11-28
2021-03-31$259.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-10
$247.12M
10-Q · filed 2022-05-10
$240.13M
derived: sum of 3 quarters · filed 2022-11-28
$233.23M
derived: sum of 4 quarters · filed 2022-11-28
2020-12-31-$12.55M
10-Q · filed 2022-02-02
-$19.53M
derived: sum of 2 quarters · filed 2022-11-28
-$26.43M
derived: sum of 3 quarters · filed 2022-11-28
-$47.29M
derived: sum of 4 quarters · filed 2022-11-28
2020-09-30-$6.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28
-$13.88M
derived: sum of 2 quarters · filed 2022-11-28
-$34.74M
derived: sum of 3 quarters · filed 2022-11-28
-$63.51M
10-K · filed 2022-11-28
-$63.51M
10-K · filed 2020-11-23
2020-06-30-$6.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-05
-$27.76M
derived: sum of 2 quarters · filed 2021-08-05
-$56.53M
10-Q · filed 2021-08-05
-$56.53M
10-Q · filed 2020-08-05
-$71.67M
derived: sum of 4 quarters · filed 2021-11-22
2020-03-31-$20.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-04
-$49.63M
10-Q · filed 2021-05-04
-$49.63M
10-Q · filed 2020-05-07
-$64.77M
derived: sum of 3 quarters · filed 2021-11-22
-$87.45M
derived: sum of 4 quarters · filed 2021-11-22
2019-12-31-$28.77M
10-Q · filed 2021-02-04
-$28.77M
10-Q · filed 2020-02-05
-$43.91M
derived: sum of 2 quarters · filed 2021-11-22
-$66.59M
derived: sum of 3 quarters · filed 2021-11-22
-$104.06M
derived: sum of 4 quarters · filed 2021-11-22
2019-09-30-$15.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22
-$37.82M
derived: sum of 2 quarters · filed 2021-11-22
-$75.29M
derived: sum of 3 quarters · filed 2021-11-22
$82.80M
10-K · filed 2021-11-22
$82.80M
10-K · filed 2019-11-25
2019-06-30-$22.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05
-$60.16M
derived: sum of 2 quarters · filed 2020-08-05
$97.94M
10-Q · filed 2020-08-05
$97.00M
derived: sum of 4 quarters · filed 2020-11-23
2019-03-31-$37.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07
$120.62M
10-Q · filed 2020-05-07
$119.68M
derived: sum of 3 quarters · filed 2020-11-23
$119.06M
derived: sum of 4 quarters · filed 2020-11-23
2018-12-31$158.10M
10-Q · filed 2020-02-05
$157.15M
derived: sum of 2 quarters · filed 2020-11-23
$156.53M
derived: sum of 3 quarters · filed 2020-11-23
$156.22M
derived: sum of 4 quarters · filed 2020-11-23
2018-09-30-$942.60K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-23
-$1.56M
derived: sum of 2 quarters · filed 2020-11-23
-$1.87M
derived: sum of 3 quarters · filed 2020-11-23
-$5.27M
10-K · filed 2020-11-23
2018-06-30-$621.80K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-05
-$931.80K
derived: sum of 2 quarters · filed 2019-08-05
-$4.33M
10-Q · filed 2019-08-05
2018-03-31-$310.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-08
-$3.70M
10-Q · filed 2019-05-08
2017-12-31-$3.39M
10-Q · filed 2019-02-07
2017-09-30$157.98K
10-K · filed 2019-11-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Alkermes plc. (ALKS)$6.844B132.74